GeNeuro’s Causal Approach To MS Treatment Gathers Momentum

29 Sep 2016

• By Sukaina Virji

GeNeuro is making good progress on its mid-stage clinical compound that is tackling a potential cause of multiple sclerosis. An early collaboration with Servier puts the Swiss biotech on a good footing if an ongoing Phase IIb trial – due to report interim data at the end of next year – is successful.

Neurons and nervous system. 3d render of nerve cells

GeNeuro SA has hit the halfway mark of its proof-of-concept trial ahead of schedule, recently enrolling the 130th patient in the CHANGE-MS Phase IIb study of GNbAC1 in patients with relapsing-remitting multiple sclerosis (RRMS).

GNbAC1 is a monoclonal antibody designed to neutralize MSRV-Env, a human endogenous retroviral (HERV) genetic element that is silent in healthy people but ubiquitously expressed in MS lesions. Its origins...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

02 Jun 2025

• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

30 May 2025

• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

27 May 2025

• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.